Lung Radiofrequency Ablation for the Treatment of Unresectable Recurrent Non-Small-Cell Lung Cancer After Surgical Intervention

Kodama, Hiroshi; Yamakado, Koichiro; Takaki, Haruyuki; Kashima, Masataka; Uraki, Junji; Nakatsuka, Atsuhiro; Takao, Motoshi; Taguchi, Osamu; Yamada, Tomomi; Takeda, Kan

doi:10.1007/s00270-011-0220-0

Cited by 57 publications

(37 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The major and minor complication rates based on CTCAE have been reported to be 6-13% and 28-40%, respectively [11,12,17]; our results appear to be comparable with these previous reports. Because lung RFA is principally performed for high-risk non-surgical candidates with advanced age or many comorbid diseases, it is important to be cautious in performing the procedure, and close follow-up after treatment is necessary.…”

Section: Discussionsupporting

confidence: 82%

“…However, some patients cannot undergo surgery because of poor respiratory function, advanced age, or comorbid disease. Recently, radiofrequency ablation (RFA) of the lung for patients who are not surgical candidates has been reported to achieve comparable results to surgical resection [11][12][13][14][15][16][17][18][19]. However, the availability of this treatment in Japan and re- ports on its outcomes from this country are limited because of lack of coverage within the national health insurance system.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Utility and Safety of Radiofrequency Ablation for Malignant Lung Tumors: Preliminary Results

Hasegawa

Sato

Inaba

et al. 2017

Interventional Radiology

View full text Add to dashboard Cite

Purpose: We evaluated the clinical usefulness and safety of radiofrequency ablation (RFA) for the treatment of lung tumors.Materials and Methods: This retrospective study included patients who underwent RFA for the treatment of lung tumors at our institution from March 2006 to April 2015. Technical success, safety, local tumor progression, and survival were evaluated.Results: In total, 41 patients (28 men and 13 women; median age, 69 years; range 37-88 years) with 51 malignant lung tumors measuring 0.6-6.8 cm (mean, 1.71.2 cm) completed 46 planned RFA sessions. Lung tumors were primary in 22 patients and metastatic in 19 patients. Four tumors were not completely surrounded by an ablation zone on computed tomography immediately after RFA (technical success rate; 91.3%, 42/46). One of 41 patients (2.4%) died of pneumonia in the contralateral lung 26 days after RFA. Grade 2 symptomatic pneumothorax (n = 5) and hemothorax (n = 1) and grade 1 asymptomatic pneumothorax (n = 9) occurred during the procedure. Grade 3 pneumonia (n = 1) and grade 2 fever (n = 2) occurred within 30 days of follow-up. During a mean follow-up period of 20.319.1 months, local tumor progression developed in 8 of 51 tumors (15.7%). Eleven patients (26.8%) died of cancer progression (n = 9) or pneumonia (n = 2). The 5-year overall survival rate was 53.5% (95% confidence interval, 31.1-75.9%). Tumor size was a significant prognostic factor on Cox proportional hazards analysis.Conclusion: RFA was a safe and useful treatment option for malignant lung tumors.

show abstract

Section: Discussionsupporting

confidence: 82%

Section: Introductionmentioning

confidence: 99%

The Clinical Utility and Safety of Radiofrequency Ablation for Malignant Lung Tumors: Preliminary Results

Hasegawa

Sato

Inaba

et al. 2017

Interventional Radiology

View full text Add to dashboard Cite

show abstract

“…A total of 55 lung RFA sessions were performed for a 5-year overall survival rate of 55.7%. Tumor size was an independent prognostic factor in multivariate analysis, with 60.5% 5-year survival in 38 patients who had NSCLC measuring \3 cm [63].…”

Section: Outcomes and Effectivenessmentioning

confidence: 98%

Standards of Practice: Guidelines for Thermal Ablation of Primary and Secondary Lung Tumors

Pereira

Salvatore²

2012

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

“…The Table provides an overview of representative publications and their results. The best survival figures reported to date (n = 44 patients; follow-up: 28.6 months) are 97% at one year, 73% at three years, and 56% at five years (26).…”

Section: Resultsmentioning

confidence: 98%

“…Cutaneous metastases (tumor seeding) at the electrode insertion site have been described in individual cases (37). Several authors recommend withdrawing the RF probe slowly and performing track ablation in order to prevent hemorrhages from the needle track and seeding of tumor cells (26,38,39).…”

Section: Complicationsmentioning

confidence: 99%

Thermal Ablation of Malignant Lung Tumors

Schneider

Herth²,

Dienemann³

2013

Deutsches Ärzteblatt International

View full text Add to dashboard Cite

SUMMARYBackground: About 50 000 new cases of non-small-cell carcinoma of the lung are diagnosed in Germany each year. More than 20% of the affected patients cannot be offered radical resection because of comorbidity alone. The lung is also the second most common site of distant metastases of extrathoracic tumors; it is the only site of such metastases in 20% of cases. In recent years, image-guided thermoablation has been used with increasing frequency in patients who are unable to undergo surgery for medical reasons.

show abstract

Lung Radiofrequency Ablation for the Treatment of Unresectable Recurrent Non-Small-Cell Lung Cancer After Surgical Intervention

Abstract: Our results suggest that lung RF ablation is a safe and useful therapeutic option for obtaining long-term survival in treated patients.

Cited by 57 publications

References 13 publications

The Clinical Utility and Safety of Radiofrequency Ablation for Malignant Lung Tumors: Preliminary Results

The Clinical Utility and Safety of Radiofrequency Ablation for Malignant Lung Tumors: Preliminary Results

Standards of Practice: Guidelines for Thermal Ablation of Primary and Secondary Lung Tumors

Thermal Ablation of Malignant Lung Tumors

Contact Info

Product

Resources

About